(Q41003368)

25 September 2017

title

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis (English)

1 reference

25 September 2017

0 references

1

1 reference

25 September 2017

5

L Alfredsson

1 reference

25 September 2017

8

T Olsson

1 reference

25 September 2017

L Forsberg

2

1 reference

25 September 2017

N Nordin

3

1 reference

25 September 2017

C Kiesel

4

1 reference

25 September 2017

J Askling

6

1 reference

25 September 2017

J Hillert

7

1 reference

25 September 2017

F Piehl

9

1 reference

25 September 2017

publication date

28 April 2015

1 reference

Multiple Sclerosis Journal

25 September 2017

published in

1 reference

25 September 2017

volume

22

1 reference

25 September 2017

issue

1

1 reference

25 September 2017

page(s)

85-93

1 reference

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

High nationwide prevalence of multiple sclerosis in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Smokers run increased risk of developing anti-natalizumab antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

A changing treatment landscape for multiple sclerosis: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

Fingolimod after natalizumab and the risk of short-term relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515579216

21 January 2018

Identifiers

DOI

10.1177/1352458515579216

1 reference

25 September 2017

1 reference